Salute e Benessere

Protein Expression Market to Reach $5 Billion by 2032, Growing at a CAGR of 7.6%…

The significant growth of the protein expression market is driven by the rapidly expanding biopharmaceutical sector, increasing demand for recombinant proteins across therapeutic and research applications, and substantial government initiatives supporting life science research and development. The market's expansion is fueled by the growing adoption of biosimilars in oncology and autoimmune diseases, emerging opportunities in underpenetrated economies, and the critical need for advanced protein…

Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

Industry analysts now estimate the global oncology drug market could surpass US$900 billion by 2034, fueled by rising demand for precision diagnostics and immune-driven treatments. For investors, the sector represents a timely opportunity to support the next wave of cancer-fighting innovation. Industry analysts now estimate the global oncology drug market couldsurpassUS$900 billion by 2034, fueled by rising demand for precision diagnostics and immune-driven treatments. For investors, the...

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025Copenhagen, Denmark, June 30, 2025– Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company…

Whole Genome Sequencing Market to Reach $8.35 Billion by 2032, Growing at a CAGR…

The growth of the whole genome sequencing market is driven by declining costs of sequencing, increasing prevalence of cancer and genetic disorders, growing utilization of whole genome sequencing in disease diagnostics and precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory and reimbursement scenarios, rising healthcare expenditures, increasing funding for research activities, growing need for early detection and prevention of diseases, technological…

Sterilization Equipment Market to Reach $29.2 Billion by 2032, Growing at a CAGR…

The growth of the sterilization equipment market is primarily driven by the increasing prevalence of hospital-acquired infections, a rise in surgical procedures, and an enhanced focus on sterilization within the food industry to mitigate food-borne illnesses. Additionally, there is growing demand for sterilization equipment from pharmaceutical and biotechnology sectors, alongside a trend toward outsourcing sterilization processes to specialized service providers in non-healthcare industries. ...

Medical Displays Market to Hit US$3.45 Billion by 2030 -- A Strategic Growth…

The global medical display market, valued at US$2.50 billion in 2024, stood at US$2.64 billion in 2025 and is projected to advance at a resilient CAGR of 5.5% from 2025 to 2030, culminating in a forecasted valuation of US$3.45 billion by the end of the period. This growth is driven by rising chronic disease burdens, an aging global population, and increased investment in high-resolution diagnostic imaging. As healthcare infrastructure modernizes and surgical precision becomes non-negotiable…

Neurogenomics Market to Reach $5.48 Billion by 2032, Growing at a CAGR of 17%…

The growth of the neurogenomics market is driven by decreasing sequencing costs, the rising prevalence of neurological disorders, and the increasing adoption of advanced sequencing technologies for disease diagnostics and precision medicine. Additional drivers include increased pharmaceutical R&D expenditures, improvements in regulatory and reimbursement frameworks for gene sequencing, rising healthcare expenditures, and increased funding for research activities. There is also a growing…

IVD Assay Development Market to Reach $9.15 Billion by 2032, Growing at a CAGR…

The growth of the IVD assay development market is driven by the rising prevalence of chronic diseases and the increasing geriatric population, the high burden of infectious diseases, the growing focus on the development of point-of-care (POC) IVD assays, and rising healthcare expenditures. The market's expansion is further fueled by emerging economies and the adoption of advanced technologies in IVD assay development, creating significant growth opportunities for stakeholders. The growth of...

AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T…

"We are thrilled to have been selected by AMED to participate in its program to strengthen the Japan Pharmaceutical Startup Ecosystem. Lymphomas and leukemias remain an area of high unmet medical need in all parts of the world, including Japan, and we are delighted to collaborate directly with many key opinion leaders and a broad set of stakeholders in this region to bring forward a truly paradigm-shifting therapeutic with meaningful benefit to patients" said Andrew Schiermeier, Ph.D…

Autoimmune Disease Diagnostics Market to Reach $11.45 Billion by 2032, Growing…

The growth of the autoimmune disease diagnostics market is driven by the increasing prevalence of autoimmune disorders, the growing emphasis on early diagnosis, and the rising awareness regarding autoimmune diseases. The market's expansion is fueled by advanced biosensor technologies, sophisticated diagnostic solutions, and the critical need for rapid and accurate detection of autoimmune conditions across diverse patient populations. The growth of the autoimmune disease diagnostics marketis...

AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway

VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative AI apps demonstrating real value. The next wave of AI's healthcare transformation is already taking shape—led by intelligent agents, next-gen diagnostics, and predictive drug discovery platforms. Behind the scenes, a new class of innovators is making tangible progress, with companies like Avant Technologies, Inc. (OTCQB: AVAI)…

Completion of Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program was expected to be completed no later than July 10, 2025.The following transactions were...

Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in…

Er-Kim will distribute KIMMTRAK® (tebentafusp) for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, in accordance with applicable local regulations in the agreed regions Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that they have been appointed by Immunocore (Nasdaq: IMCR) as the distribution and commercialization partner for KIMMTRAK, for the treatment of...

SciBase announces outcome in directed share issue

Allotment of sharesAll shares in the Directed Issue have been subscribed for and the board of directors has therefore today, on 30 June 2025, resolved to allot shares to Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS and Ribbskottet AB. Allotment of sharesAll shares in the Directed Issue have been subscribed for and the board of directors has therefore today, on30 June 2025, resolved to allot shares to Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS and Ribbskottet AB...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary…

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S. 1 Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of...

Affidea Group selects b-rayZ as its preferred AI partner in breast imaging…

Affidea, a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that it has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging. Breast cancer diagnostics often face fragmentation, with critical information scattered across different modalities and specialists. This can slow down decision-making and delay life-saving treatments. b-rayZ’s AI-powered...

PlaDeo: Europe Debut for the World's First Bio-Plasma Powered Deodorant Device

Unlike traditional deodorants that use aluminum salts, alcohol, or synthetic fragrances, PlaDeo harnesses reactive oxygen species (ROS) — specifically hydroxyl radicals (OH⁻) and superoxide ions (O₂⁻) — to neutralize odor-causing bacteria directly on the skin. No masking. No chemicals. Backed by clinical evidence, PlaDeo offers next-generation odor control through nature-inspired bio-plasma technology. Unlike traditional deodorants that use aluminum salts, alcohol, or synthetic fragrances,...

ESTEVE to acquire medicine to treat medullary thyroid cancer

"Medullary thyroid carcinoma is a rare neuroendocrine tumor that can produce calcitonin from parafollicular cells. The primary treatment is surgery. However, treatments like vandetanib can often slow down or even partially reverse the tumour growth2. We at ESTEVE are proud to join the fighting effort of the patients diagnosed with this carcinoma and their healthcare professionals, with the ambition to continue improving patient's health and lives", confirms José María Giménez-Arnau…

Hansa Biopharma presents positive outcomes of five-year follow-up study of…

The extended pooled analysis, including data from the 17-HMedIdeS-14 study, showed sustained positive outcomes out to five years of highly sensitized patients who received an imlifidase-enabled kidney transplant. After five years, the patient survival rate was 90% (reflecting three deaths occurring between six months and one year) and graft survival (death censored) was 82%, in line with outcomes seen at three-years.2 At five years, mean estimated glomerular filtration rate (eGFR) or kidney…

AB Science provides an update on the renegotiation of loan repayment terms with…

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON THE RENEGOTIATION OF LOAN REPAYMENT TERMS WITH ITS FINANCIAL CREDITORS AGREEMENT IN PRINCIPLE HAS BEEN REACHED ON A TWO-YEAR DEFERRAL OF REPAYMENT OF STATE-GUARANTEED LOANS SAVINGS OVER THE PERIOD WILL BE INVESTED IN R&DTHIS AGREEMENT IS CONDITIONAL ON THE REPAYMENT DATE OF THE EIB COVID LOAN BEING POSTPONED, NEGOTIATIONS ON WHICH ARE CURRENTLY UNDERWAY. Paris, June 30, 2025, 8am CETAB Science SA(Euronext -...

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the…

The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with…

Bastide Groupe Sells Baywater Healthcare To Sapio Group

Crewe, United Kingdom & Monza, Italy - 30th June 2025 Bastide le Confort Medical SA (hereinafter “Groupe Bastide”) today announced that it has agreed to the sale of its subsidiary Baywater Healthcare UK Limited (hereinafter “Baywater Healthcare” or “Company”), a leading provider of home oxygen services (“HOS”) and respiratory homecare in the UK, to the Sapio S…

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial

Press ReleaseNicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025New Drug Application (NDA) submission in the U.S. targeted for H1 2026June 30, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient has completed the Denali Phase 3 trial, evaluating the...

Press release: Availability of the Q2 2025 Aide mémoire

Availability of the Q2 2025 Aide mémoireParis, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second...

Altri Comunicati